Apyx Medical (NASDAQ:APYX) Shares Break Above 50-Day Moving Average - Time to Sell?

Key Points

• Shares rose above their 50-day moving average: Apyx Medical traded as high as $3.11, above the $2.74 average, and last traded at $3.045.
• Third-quarter results beat estimates: Revenue was $14.03 million versus $13.29 million expected, and the $0.04-per-share loss was narrower than forecast. Surgical Aesthetics revenue grew 17%; Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million and lowered its operating-expense target.
• Profitability remains a challenge: The company continued to post a quarterly loss and negative net margins. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $6.50.

Apyx Medical Corporation (NASDAQ:APYX - Get Free Report)'s stock price passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $2.74 and traded as high as $3.11. Apyx Medical shares last traded at $3.0450, with a volume of 994,957 shares traded.

Key Stories Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q3 revenue was $14.0 million, above the $13.29 million analyst estimate, while the loss of $0.04 per share was narrower than consensus estimates of $0.07–$0.09. Surgical Aesthetics revenue grew 17%. Apyx Medical Q3 2026 financial results
• Positive Sentiment: Management tightened its 2026 operating expense target to $41 million–$42.5 million, indicating a greater focus on cost control. Apyx reaffirms guidance and tightens expense target
• Neutral Sentiment: Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million, broadly in line with the $59.4 million consensus estimate. The company also reported a successful commercial launch of its AYON power liposuction handpiece. Apyx Medical Q3 2026 financial results
• Negative Sentiment: The company continued to post a quarterly loss and has negative net margins, so sustained revenue growth and expense control will be important to improving profitability.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on APYX shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Apyx Medical in a research report on Monday, September 21st. HC Wainwright began coverage on shares of Apyx Medical in a report on Monday, July 13th. They issued a "buy" rating and a $7.00 price objective on the stock. Zacks Research raised shares of Apyx Medical to a "hold" rating in a report on Tuesday, July 14th. Finally, Maxim Group initiated coverage on shares of Apyx Medical in a research note on Tuesday, September 29th. They issued a "buy" rating and a $6.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $6.50.

Apyx Medical Price Performance

The firm has a market cap of $128.27 million, a PE ratio of -15.22 and a beta of 1.47. The stock has a 50 day simple moving average of $2.74 and a two-hundred day simple moving average of $3.59. The company has a debt-to-equity ratio of 3.19, a quick ratio of 4.53 and a current ratio of 5.68.

Apyx Medical (NASDAQ:APYX - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.05. The firm had revenue of $14.03 million for the quarter, compared to the consensus estimate of $13.29 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. Sell-side analysts expect that Apyx Medical Corporation will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On Apyx Medical

Several hedge funds have recently bought and sold shares of APYX. Nantahala Capital Management LLC acquired a new position in shares of Apyx Medical in the 2nd quarter valued at $14,683,414. AIGH Capital Management LLC purchased a new stake in Apyx Medical during the second quarter worth $5,066,000. BlackRock Inc. acquired a new stake in Apyx Medical during the second quarter valued at $2,519,000. Sei Investments Co. grew its position in Apyx Medical by 298.6% during the first quarter. Sei Investments Co. now owns 598,255 shares of the company's stock valued at $2,208,000 after buying an additional 448,174 shares during the period. Finally, Renaissance Technologies LLC grew its position in Apyx Medical by 37.2% during the first quarter. Renaissance Technologies LLC now owns 302,395 shares of the company's stock valued at $1,116,000 after buying an additional 82,000 shares during the period. Hedge funds and other institutional investors own 55.33% of the company's stock.

About Apyx Medical

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company's platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical's principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.